Treatment of the First Patient in XanADu Marks Landmark in Alzheimer’s Disease Trial

Actinogen Medical (ASX: ACW) is delighted to announce the treatment of the first patient in XanADu, its Phase II clinical trial of Xanamem in Alzheimer’s disease. This is the first patient to be enrolled into XanADu globally, and represents a significant milestone following more than a decade of research undertaken by Edinburgh University in Scotland and Actinogen Medical in Australia, to develop Xanamem as a promising new treatment for Alzheimer’s disease.

KEY TAKEAWAYS:

• Actinogen Medical reaches a major milestone with the first patient enrolled into XanADu – its Phase II clinical trial of Xanamem™ in Alzheimer’s disease.
• The first trial patient was treated at the Central Coast Neurosciences Research site in New South Wales, Australia.
• This marks a defining moment in the development of Xanamem following more than a decade of research.
• Xanamem blocks excess production of cortisol, the stress hormone, in the brain and represents a promising new approach to treat Alzheimer’s disease.
• XanADu will enrol 174 patients at 20 research sites in the USA, the UK and Australia with the final patientexpected in Q4 2018 and top-line results in Q1 2019.

Alzheimer’s expert Professor Colin Masters, AO, Laureate Professor at The University of Melbourne, one of the AIBL study’s key authors and a member of Actinogen’s Scientific Advisory Board, said Xanamem could provide the turning-point needed in finding a new effective treatment for Alzheimer’s disease.

“Earlier this year, the AIBL study, a 1100+ participant, 9-year study published data showing that raised cortisol is strongly associated with the development of Alzheimer’s disease. Xanamem, through its inhibition of cortisol in the brain, could represent a major advance in the treatment of Alzheimer’s,” he said.

“I am delighted that Australia is at the forefront of global Alzheimer’s research in initiating the XanADu trial, evaluating Xanamem as a treatment for this devastating disease.”

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Actinogen Medical is developing Xanamem a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential.

Request Information